SciGen is a high growth biopharmaceutical company that develops, manufactures and markets recombinant human health care biotechnology derived products. SciGen's focus is in the areas of endocrinology, gastroenterology and immunology. The companys portfolio consists of biosimilar products such as rhuman growth hormone, rhuman insulin and rhuman GCSF. All of SciGens products have undergone substantial clinical development.

SciGens strategy is to focus on biosimilars (follow-on proteins) in order to minimize the risk of early stage product development. SciGen also collaborates with strategic partners and institutions in order to continuously fill & improve its pipeline.

SciGen also in-licenses and distributes pharmaceutical products and medical devices.